Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2006

Open Access 01-12-2006 | Primary research

"Nutritional and chemopreventive anti-cancer agents up-regulate expression of p27Kip1, a cyclin-dependent kinase inhibitor, in mouse JB6 epidermal and human MCF7, MDA-MB-321 and AU565 breast cancer cells"

Author: Isao Eto

Published in: Cancer Cell International | Issue 1/2006

Login to get access

Abstract

Background

p27(Kip1) is a cyclin-dependent kinase inhibitor. When up-regulated, p27 inhibits G1-to-S phase transition of the cell cycle. This report addresses the question of whether various nutritional and chemopreventive anti-cancer agents up-regulate the expression of p27 in preneoplastic and neoplastic cells.

Results

Experimental evidence presented in the first half of this report shows that these agents fairly faithfully up-regulate expression of p27 in mouse epidermal (JB6) and human breast cancer (MCF7, MDA-MB-321, and AU565) cells. Up-regulation appears to be specific to p27 because expression of cyclin D1, E, and A, and p21Cip1/Waf1 was not modulated by these agents. Up-regulation of the expression of p27 is likely due to the activation of translation rather than transcription of p27 because (a) up-regulation is mediated by the 5'-untranslated region (-575) of the p27 gene and (b) the antibiotic actinomycin D, an inhibitor of transcription, did not attenuate the up-regulation of p27. This latter finding is likely to preclude the existence of cryptic transcription factor binding site(s) in the 5'-untranslated region of p27 gene. The experimental evidence, presented in the second half of this report, was obtained using the 5'-untranslated region (-575) of p27 gene. The evidence suggests that cancer preventive agents up-regulate expression of p27 by at least four different molecular signaling pathways: (a) Caloric restriction is likely to up-regulate p27 expression via 5'-AMP-activated protein kinase (AMPK; a metabolic energy sensor or cellular fuel gauge), tuberous sclerosis complex (TSC), and mammalian target of rapamycin (mTOR). Amino acid deficiencies also up-regulate the expression of p27 using some components of this pathway. (b) 4-Hydroxytamoxifen (but not tamoxifen), genistein (but not genistin), daidzein, and probably other nutritional and chemopreventive anti-cancer agents could up-regulate expression of p27 via receptor protein tyrosine kinases (RPTKs), phosphoinositide 3-kinase (PI3K), phosphoinosite-dependent kinase (PDK), Akt/PKB and mTOR. (c) Expression of p27 could also be up-regulated via RPTKs followed by MAPKs – MEK, ERK and p38MAPK – and probably MNK. Finally, (d) global hypomethylation of 5'-m7G cap of mRNAs could also up-regulate expression of p27.

Conclusion

Based on these findings, we conclude that various nutritional and chemopreventive anti-cancer agents up-regulate expression of p27 in (pre)neoplastic cells.
Appendix
Available only for authorised users
Literature
1.
Hengst L: A second RING to destroy p27 Kip1 . Nature Cell Biol. 2004, 6: 1153-1155. 10.1038/ncb1204-1153.CrossRefPubMed
2.
Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A, Pestell RG: Transforming p21 ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem. 1995, 270: 23589-23597. 10.1074/jbc.270.31.18301.CrossRefPubMed
3.
Henglein B, Chenivesse X, Wang J, Eick D, Brechot C: Structure and cell cycle-regulated transcription of the human cyclin A gene. Proc Natl Acad Sci USA. 1994, 91: 5490-5494. 10.1073/pnas.91.12.5490.PubMedCentralCrossRefPubMed
4.
Minami S, Ohtani-Fujita N, Igata E, Tamaki T, Sakai T: Molecular cloning and characterization of the human p27Kip1 gene promoter. FEBS Lett. 1997, 411: 1-6. 10.1016/S0014-5793(97)00660-1.CrossRefPubMed
5.
Kullmann M, Gopfert U, Siewe B, Hengst L: ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5'UTR. Genes Dev. 2002, 16: 3087-3099. 10.1101/gad.248902.PubMedCentralCrossRefPubMed
6.
Gopfert U, Kullmann M, Hengst L: Cell cycle-dependent translation of p27 involves a responsive element in its 5'-UTR that overlaps with a uORF. Hum Mol Genet. 2003, 12: 1767-1779. 10.1093/hmg/ddg177.CrossRefPubMed
7.
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell. 1993, 75: 817-825. 10.1016/0092-8674(93)90500-P.CrossRefPubMed
8.
Hsu TC, Nair R, Tulsian P, Camalier CE, Hegamyer GA, Young MR, Colburn NH: Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-κB activation. Cancer Res. 2001, 61: 4160-4168.PubMed
9.
Liu Z, Kokunai T, Tamaki N: Tamoxifen interacts with NEU/c-ERBB-2 receptor and inhibits growth of human malignant glioma cell lines. Kobe J Med Sci. 2001, 47: 131-140.PubMed
10.
Nedeljkovic A, Radulovic S, Bjelogrlic S: Pleiotropic effect of genistein makes it a promising cancer protective compound. Arch Oncol. 2001, 9: 171-174.
11.
Sah JF, Balasubramanian S, Eckert RL, Rorke EA: Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and Akt kinases. J Biol Chem. 2004, 279: 12755-12762. 10.1074/jbc.M312333200.CrossRefPubMed
12.
Masuda M, Suzui M, Lim JT, Weinstein IB: Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res. 2003, 9: 3486-3491.PubMed
13.
Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSC-mTOR pathway in human disease. Nature Genetics. 2005, 37: 19-24. 10.1038/ng1494.CrossRefPubMed
14.
Ohanna M, Sobering AK, Lapointe T, Lorenzo L, Praud C, Petroulakis E, Sonenberg N, Kelly PA, Sotiropoulos A, Pende M: Atrophy of S6K1-/- skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nature Cell Biol. 2005, 7: 286-294. 10.1038/ncb1231.CrossRefPubMed
15.
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001, 108: 1167-1174. 10.1172/JCI200113505.PubMedCentralCrossRefPubMed
16.
Agrawal D, Hauser P, McPherson F, Dong F, Garcia A, Pledger WJ: Repression of p27Kip1 synthesis by platelet-derived growth factor in BALBc/3T3 cells. Mol Cell Biol. 1996, 16: 4327-4336.PubMedCentralCrossRefPubMed
17.
Hengst L, Reed SI: Translational control of p27Kip1 accumulation during the cell cycle. Science. 1996, 271: 1861-1864.CrossRefPubMed
18.
Millard SS, Yan JS, Nguyen H, Pagano M, Kiyokawa H, Koff A: Enhanced ribosomal association of p27(Kip1) mRNA in a mechanism contributing to accumulation during growth arrest. J Biol Chem. 1997, 272: 7093-7098. 10.1074/jbc.272.11.7093.CrossRefPubMed
19.
Miskimins WK, Wang G, Hawkinson M, Miskimins R: Control of cyclin-dependent kinase inhibitor p27 expression by cap-independent translation. Mol Cell Biol. 2001, 21: 4960-4967. 10.1128/MCB.21.15.4960-4967.2001.PubMedCentralCrossRefPubMed
20.
Millard SS, Vidal A, Markus M, Koff A: A U-rich element in the 5' untranslated region is necessary for the translation of p27 mRNA. Mol Cell Biol. 2000, 20: 5947-5959. 10.1128/MCB.20.16.5947-5959.2000.PubMedCentralCrossRefPubMed
21.
22.
Hardie DG: The AMP-activated protein kinase pathway – new players upstream and downstream. J Cell Sci. 2004, 117: 5479-5487. 10.1242/jcs.01540.CrossRefPubMed
23.
Nicholson KM, Anderson NG: The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal. 2002, 14: 381-395. 10.1016/S0898-6568(01)00271-6.CrossRefPubMed
24.
Hinault C, Mothe-Satney I, Gautier N, Lawrence JC, Van Obberghen E: Amino acids and leucine allow insulin activation of the PKB/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from db/db mice. FASEB J. 2004, 18: 1894-1896.PubMed
25.
Knauf U, Tschopp C, Gram H: Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol Cell Biol. 2001, 21: 5500-5511. 10.1128/MCB.21.16.5500-5511.2001.PubMedCentralCrossRefPubMed
26.
Shatkin AJ, Manley JL: The ends of the affair: capping and polyadenylation. Nat Struct Biol. 2000, 7: 838-842. 10.1038/79583.CrossRefPubMed
27.
Shuman S, Lima CD: The polynucleotide ligase and RNA capping enzyme superfamily of covalent nucleotidyltransferases. Curr Opin Struct Biol. 2004, 14: 757-764. 10.1016/j.sbi.2004.10.006.CrossRefPubMed
28.
Gu M, Lima CD: Processing the message: structural insights into capping and decapping mRNA. Curr Opin Struct Biol. 2005, 15: 99-106. 10.1016/j.sbi.2005.01.009.CrossRefPubMed
29.
Holstein SA, Wohlford-Lenane CL, Hohl RJ: Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB. J Biol Chem. 2002, 277: 10678-10682. 10.1074/jbc.M111369200.CrossRefPubMed
30.
Jiang H, Coleman J, Miskimins R, Miskimins WK: Expression of constitutively active 4EBP-1 enhances p27Kip1 expression and inhibits proliferation of MCF7 breast cancer cells. Cancer Cell Int. 2003, 3: 2-10.1186/1475-2867-3-2.PubMedCentralCrossRefPubMed
31.
King TD, Song L, Jope RS: AMP-activated protein kinase (AMPK) activating agents cause dephosphorylation of Akt and glycogen synthase kinase-3. Biochem Pharmacol. 2006, 71: 1637-1647. 10.1016/j.bcp.2006.03.005.PubMedCentralCrossRefPubMed
32.
Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N: Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem. 2005, 280: 32081-32089. 10.1074/jbc.M502876200.CrossRefPubMed
33.
Suzuki A, Kusakai G, Kishimoto A, Shimojo Y, Ogura T, Lavin MF, Esumi H: IGF-1 phosphorylates AMPKα subunit in ATM-dependent and LKB1-independent manner. Biochem Biophys Res Commun. 2004, 324: 986-992. 10.1016/j.bbrc.2004.09.145.CrossRefPubMed
34.
Dokladda K, Green KA, Pan DA, Hardie DG: PD98059 and U0126 activate AMP-activated protein kinase by increasing the cellular AMP:ATP ratio and not via inhibition of the MAP kinase pathway. FEBS Lett. 2005, 579: 236-240. 10.1016/j.febslet.2004.11.084.CrossRefPubMed
35.
Rattan R, Giri S, Singh AK, Singh I: 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem. 2005, 280: 39582-39593. 10.1074/jbc.M507443200.CrossRefPubMed
36.
Longnus SL, Segalen C, Giudicelli J, Sajan MP, Farese RV, Van Obberghen E: Insulin signaling downstream of protein kinase B is potentiated by 5'AMP-activated protein kinase in rat hearts in vivo. Diabetologia. 2005, 48: 2591-2601. 10.1007/s00125-005-0016-3.CrossRefPubMed
37.
Han S, Khuri FR, Roman J: Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res. 2006, 66: 315-323. 10.1158/0008-5472.CAN-05-2367.CrossRefPubMed
38.
Davis BJ, Xie Z, Viollet B, Zou MH: Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006, 55: 496-505. 10.2337/diabetes.55.02.06.db05-1064.CrossRefPubMed
39.
Hattori Y, Suzuki K, Hattori S, Kasai K: Metformin inhibits cytokine-induced factor κB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 2006, 47: 1183-1188. 10.1161/01.HYP.0000221429.94591.72.CrossRefPubMed
40.
Soltys CL, Kovacic S, Dyck JR: Activation of cardiac AMP-activated protein kinase by LKB1 expression or chemical hypoxia is blunted by increased Akt activity. Am J Physiol Heart Circ Physiol. 2006, 290: H2472-H2479. 10.1152/ajpheart.01206.2005.CrossRefPubMed
41.
Dagon Y, Avraham Y, Berry EM: AMPK activation regulates apoptosis, adipogenesis, and lipolysis by eIF2α in adipocytes. Biochem Biophys Res Commun. 2006, 340: 43-47.CrossRefPubMed
42.
Jun T, Gjoerup O, Roberts TM: Tangled web: evidence of cross-talk between c-Raf-1 and Akt. Sci STKE. 1999, 1999: PE1-PubMed
43.
Sprenkle AB, Davies SP, Carling D, Hardie DG, Sturgill TW: Identification of Raf-1 Ser621 kinase activity from NIH 3T3 cells as AMP-activated protein kinase. FEBS Lett. 1997, 403: 254-258. 10.1016/S0014-5793(97)00062-8.CrossRefPubMed
Metadata
Title
"Nutritional and chemopreventive anti-cancer agents up-regulate expression of p27Kip1, a cyclin-dependent kinase inhibitor, in mouse JB6 epidermal and human MCF7, MDA-MB-321 and AU565 breast cancer cells"
Author
Isao Eto
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2006
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-6-20

Other articles of this Issue 1/2006

Cancer Cell International 1/2006 Go to the issue

Primary research

Lack of p53 function promotes radiation-induced mitotic catastrophe in mouse embryonic fibroblast cells

Primary research

Direct interaction between the catalytic subunit of Protein Phosphatase 1 and pRb

Primary research

Qualitative and quantitative characteristics of the extracellular DNA delivered to the nucleus of a living cell

Primary research

Decreased intracellular zinc in human tumorigenic prostate epithelial cells: a possible role in prostate cancer progression

Primary research

Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer

Primary research

Protease nexin-1 expression is altered in human breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits